Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AZ, J&J in Prostate Cancer Drug Co-promotion Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

AZ, J&J in Prostate Cancer Drug Co-promotion Pact

To market abiraterone in Japan

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AstraZeneca has entered an agreement with Johnson & Johnson to co-promote its prostate cancer drug abiraterone in Japan, expanding AZ’s presence in the country. Abiraterone was submitted for regulatory approval in Japan in July 2013. Abiraterone is currently marketed in the U.S. and Europe under the brand name Zytiga. Financial terms were not disclosed.
 
“This deal is a strong strategic fit for AstraZeneca, reinforcing both our focus on oncology as a core therapy area and Japan as one of our key growth drivers,” said Marc Dunoyer, executive vice president for global products and portfolio strategy at AZ.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters